Biologics IP – A Strategic Review (TechVision)

Profiling Patenting Activity of 13 Major Pharma-biotech Companies in the Area of Biologics

USD 4,950

* Required Fields

USD 4,950

PAY BY INVOICE

Be the first to review this product

This study provides a strategic overview of the patent activity of the 13 major pharma-biotech companies in the area of biologics. The biologics patent portfolios of these companies were analyzed and segmented by biologics type (e.g., peptides, antibodies, vaccines etc.) and therapeutic area for competitive benchmarking. This study will help pharma-biotech companies understand the competitive landscape and the available white space from patenting perspective.

Table of Contents

1.0 Executive Summary1.0 Executive Summary2.0 Research Objective and Background2.1 Research Objective2.2 Biologics versus Small Molecule2.3 Big Pharma Shifting Focus from Small Molecule to Biologics, Why?2.4 Big Pharma Gained Biologics Expertise through Mergers and Acquisitions (M&A)—Important Deals3.0 Research Scope and Methodology3.1 Research Scope and Concepts3.2 Analysis Approach3.3 Keywords and IPC Codes Used for Clustering by Biologics Type3.4 Therapeutic Areas Covered in the Study4.0 Biologics Patent Portfolios of the Top 13 Major Pharma Companies 4.1 Competitive Benchmarking of the Top 13 Major Pharma Companies Based on Their Biologics Patent Portfolios, 1996–20155.0 Overview of Biologics Patent Portfolio5.1 Company 1: Roche5.1.1 Mapping of Roche’s Patent Portfolio by Biologics Type5.1.2 Mapping of Roche’s Patent Portfolio by Therapeutic Area5.2 Company 2: GSK5.2.1 Mapping of GSK’s Patent Portfolio by Biologics Type5.2.2 Mapping of GSK’s Patent Portfolio by Therapeutic Area5.3 Company 3: Merck5.3.1 Mapping of Merck’s Patent Portfolio by Biologics Type5.3.2 Mapping of Merck’s Patent Portfolio by Therapeutic Area5.4 Company 4: Sanofi5.4.1 Mapping of Sanofi’s Patent Portfolio by Biologics Type5.4.2 Mapping of Sanofi’s Patent Portfolio by Therapeutic Area5.5 Company 5: Novartis5.5.1 Mapping of Novartis’s Patent Portfolio by Biologics Type5.5.2 Mapping of Novartis’s Patent Portfolio by Therapeutic Area5.6 Company 6: Bristol-Myers Squibb5.6.1 Mapping of Bristol-Meyers Squibb’s Patent Portfolio by Biologics Type5.6.2 Mapping of Bristol-Meyers Squibb’s Patent Portfolio by Therapeutic Area5.7 Company 7: Amgen5.7.1 Mapping of Amgen’s Patent Portfolio by Biologics Type5.7.2 Mapping of Amgen’s Patent Portfolio by Therapeutic Area5.8 Company 8: Novo Nordisk5.8.1 Mapping of Novo Nordisk’s Patent Portfolio by Biologics Type5.8.2 Mapping of Novo Nordisk’s Patent Portfolio by Therapeutic Area5.9 Company 9: Pfizer5.9.1 Mapping of Pfizer’s Patent Portfolio by Biologics Type5.9.2 Mapping of Pfizer’s Patent Portfolio by Therapeutic Area5.10 Company 10: Eli Lilly5.10.1 Mapping of Eli Lilly’s Patent Portfolio by Biologics Type5.10.2 Mapping of Eli Lilly’s Patent Portfolio by Therapeutic Area5.11 Company 11: AstraZeneca5.11.1 Mapping of AstraZeneca’s Patent Portfolio by Biologics Type5.11.2 Mapping of AstraZeneca’s Patent Portfolio by Therapeutic Area5.12 Company 12: Bayer HealthCare5.12.1 Mapping of Bayer HealthCare’s Patent Portfolio by Biologics Type5.12.2 Mapping of Bayer HealthCare’s Patent Portfolio by Therapeutic Area5.13 Company 13: AbbVie5.13.1 Mapping of AbbVie’s Patent Portfolio by Biologics Type5.13.2 Mapping of AbbVie’s Patent Portfolio by Therapeutic Area6.0 Key Findings6.1 Key FindingsLegal Disclaimer7.0 Appendix7.1 Acronyms8.0 The Frost & Sullivan Story8.1 The Frost & Sullivan Story8.2 Value Proposition: Future of Your Company & Career8.3 Global Perspective8.4 Industry Convergence8.5 360º Research Perspective8.6 Implementation Excellence8.7 Our Blue Ocean Strategy




Keyword1

Keyword2

Keyword3

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.